Statement for 72nd meeting of the WHO Regional Committee for Europe

14 September 2022 in Tel Aviv, Israel

The World Hepatitis Alliance and our 71 member organisations in Europe strongly support the adoption of the regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022–2030; and tuberculosis 2023–2030.

Every 30 seconds, a life is lost to viral hepatitis somewhere in the world.

In the WHO EURO region, nearly 29 million people live with chronic hepatitis B and C and almost 170,000 will die from hepatitis-related liver cancer and cirrhosis each year.

Governments and regional institutions must do more to reduce these deaths and the devastating impact hepatitis has on our communities. 

Stigma and discrimination continue to be a barrier to testing and care. It is clear that countries will not achieve these targets without placing equity and the needs of key populations at the centre of the epidemic response.

We believe these action plans provide an opportunity to reshape the landscape and accelerate the response through integration, new partnerships and collaboration.

We must focus on the needs of individuals and communities rather than diseases specific programmes. If we do, we can achieve universal health coverage, person-centered care and our 2030 goals.

We urge member states to implement the entirety of the plans and not leave people living with and affected by viral hepatitis behind.

At the World Hepatitis Summit in June, the Director-General of WHO, Dr Tedros told the world, “there are few diseases that we can realistically dream of eliminating, but hepatitis is one of them.” 

We can’t wait for Europe to be free from hepatitis, and together we can make it happen. Hepatitis Can’t Wait.

Cary James,

Chief Executive, World Hepatitis Alliance

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close